Cytochrome P450 2B6*5 increases relapse after cyclophosphamide-containing conditioning and autologous transplantation for lymphoma

Veronika Bachanova, Ryan Shanley, Farhana Malik, Lata Chauhan, Vishal Lamba, Daniel J. Weisdorf, Linda J. Burns, Jatinder Kaur Lamba

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) enzymes for its cytotoxicity. We evaluated the influence of single nucleotide polymorphisms (SNPs) of CYP enzymes on the efficacy of autologous hematopoietic cell transplantation (HCT) for lymphoma. SNPs of 22 genes were analyzed in 93 patients with Hodgkin (n=52) and non-Hodgkin lymphoma (n=41) treated with high-dose Cy followed by autologous HCT between 2004 and 2012. Preparative regimens contained Cy (120mg/kg) combined with carmustine/etoposide (n=61) or Cy (6000mg/m2) with total body irradiation (n=32). Lack of complete remission as measured by pretransplant positron emission tomography was the sole clinical factor associated with increased risk of relapse (HR, 2.1). In genomic analysis, we identified a single SNP (rs3211371) in exon 9 (C>T) of the CYP2B6 gene (allele designation 2B6*5) that significantly impacted patient outcomes. After adjusting for disease status and conditioning regimen, patients with the CYP2B6*1/*5 genotype had a higher 2-year relapse rate (HR, 3.3; 95% CI, 1.6 to 6.5; P=.041) and decreased overall survival (HR, 13.5; 95% CI, 3.5 to 51.9; P=.008) than patients with the wild-type allele. Two-year progression-free survival for patients with 2 hypofunctional CYP2B6 variant genotypes (*5 and *6) was only 11% (95% CI, 1% to 39%) compared with 67% (95% CI, 55% to 77%) for patients with the wild-type CYP2B6*1 allele in exon 9. Our results suggest that CYP2B6 SNPs influence the efficacy of high-dose Cy and significantly reduce the success of autologous HCT for lymphoma patients with the CYP2B6*5 variant.

Original languageEnglish (US)
Pages (from-to)944-948
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Issue number5
StatePublished - May 1 2015

Bibliographical note

Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.


  • Autologous hematopoietic cell transplantation
  • Cyclophosphamide
  • Cytochrome P450 polymorphism
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma


Dive into the research topics of 'Cytochrome P450 2B6*5 increases relapse after cyclophosphamide-containing conditioning and autologous transplantation for lymphoma'. Together they form a unique fingerprint.

Cite this